"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherap… (NCT03149107) | Clinical Trial Compass
TerminatedPhase 3
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
Stopped: Recruitment not sufficient
Germany48 participantsStarted 2016-09-01
Plain-language summary
Schizophrenia is a severe mental disorder associated with significant impairments in affective, cognitive and social functioning. Consequently, a special interest in the prevention of schizophrenia and psychotic disorders has emerged. Pharmacological as well as psychological interventions show promising preventive effects. The purpose of this multicentric study is the investigation of possible preventive effects of a treatment combination containing a psychotherapy form and medication (N-Acetylcytein - NAC) in individuals with an enhanced risk for developing schizophrenia. Both treatment forms may reduce the risk in this population due to their specific properties: The psychotherapy can improve social skills, whereas NAC is supposed to develop its protective effects on neuronal level due to its antiinflammatory properties. The investigators will examine the preventive effects by measuring transition rates to psychosis after treatment as well as improvements in social, affective and cognitive functioning.
Who can participate
Age range18 Years – 40 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 18 - 40 years;
✓. Subjects with the ability to follow study instructions and likely to attend and complete all required visits;
✓. Written informed consent of the subject;
✓. Subjects are able to speak, write and understand the German language sufficiently well (at the investigators discretion) to complete all required study procedures;
✓. Clinical High Risk Criteria : ESPRIT Ultra-high risk criteria (Attenuated Positive Symptoms and/or Brief Llimited Intermittend Psychotic Symptoms and/or a combination of familial risk or schizotypal disorder with a significant loss of functioning; severity assessed by the Structured Interview for Prodromal Syndromes, SIPS 5.0) and/or The Basic Symptom Criterion 'Cognitive Disturbances, COGDIS' (2/9 cognitive-perceptive basic symptoms; assessed by the Schizophrenia Proneness Instrument - Adult Version, SPI-A)
Exclusion criteria
✕. Known history of hypersensitivity to the investigational drug or to drugs with a similar chemical structure;
✕. Simultaneously participation in another clinical trial involving administration of an investigational medicinal product within 30 days prior to clinical trial beginning. The simultaneous participation in a noninterventional clinical trial is permitted in case the subject is nevertheless able and willing to attend and complete all required visits and in case there are no other contraindications;
What they're measuring
1
Transition to psychosis
Timeframe: I. After intervention phase (26 weeks after trial start) and II. as follow-up (78 weeks after trial start)
2
Psychosocial functioning
Timeframe: I. After intervention phase (26 weeks after trial start) and II. as follow-up (78 weeks after trial start)
✕. Subjects with a physical or psychiatric condition which at the investigator's discretion may put the subject at other clinically significant risks than those that are defined as outcome of this study (development of a first psychotic episode, functional deterioration), may confound the trial results, or may interfere with the subject's per protocol participation in this clinical trial;
✕. Acute Suicidality;
✕. Known substance abuse or dependence according to DSM-IV-TR;
✕. Patients with hepatic or renal failure, or with known problems of galactose intolerance, clinically significant lactase deficiency or glucose-galactose malabsorption or histamine-intolerance;
✕. Subjects with known asthma bronchiale;
✕. Subjects with a history of gastrointestinal ulcer;